CARsgen submits dual IND for allogeneic BCMA CAR T product
December 29, 2025 | 14:35
The company has filed applications to begin clinical trials for its off-the-shelf cell therapy targeting multiple myeloma.
CARsgen Satri-cel Phase I Data at ESMO 2025: Early Signal in Adjuvant Pancreatic Cancer
October 20, 2025 | 16:09
Preliminary response rates suggest cell therapy may extend beyond haematology, although durability metrics remain necessary to assess true clinical benefit.
CARsgen Wins GPC3 CAR-T Patent Battle at EPO
July 14, 2025 | 10:00
Innovation secured — the biotech firm defends its breakthrough in cancer therapy with a legal victory.
CARsgen showcases Satri-cel breakthroughs at ASCO 2025 and in The Lancet
June 02, 2025 | 16:29
Dual milestone affirms Satri-cel’s potential in solid tumour immunotherapy and advances CAR-T research.
CARsgen's Satri-cel Immunotherapy Makes ASCO Debut
May 23, 2025 | 08:00
The CAR-T cell therapy candidate garners attention for its potential in solid tumor treatment.
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
December 30, 2024 | 20:50
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-ST-01.
Mobile Version